Topic
Barbexaclone
About: Barbexaclone is a research topic. Over the lifetime, 18 publications have been published within this topic receiving 55 citations. The topic is also known as: Barbexaclon & Barbexaclona.
Papers
TL;DR: A 33-year-old female suffering from frequent complex-partial seizures who developed a non-convulsive status epilepticus after one week of antiepileptic therapy with valproate (VPA) which had been added to a basic medication with barbexaclone (BBC) in rapidly increasing dosage is reported.
Abstract: We report on a 33-year-old female suffering from frequent complex-partial seizures who developed a nonconvulsive status epilepticus after one week of antiepileptic therapy with valproate (VPA) which had been added to a basic medication with barbexaclone (BBC) in rapidly increasing dosage. The electroencephalogram (EEG) showed continuous rhythmic generalized sharp and slow wave activity with a frontal maximum. Intravenous administration of 3.0 mg of the benzodiazepine (BZ) receptor antagonist flumazenil under monitoring with video-EEG led to an immediate and marked electroclinical improvement, whereas 6.0 mg of the BZ receptor agonist midazolam was followed by a deterioration both clinically and in the EEG. We discuss the concept of VPA-encephalopathy and the possible mechanisms of the action of flumazenil on VPA-induced as well as on other toxic and metabolic encephalopathies. Flumazenil might antagonize increased benzodiazepine receptor activity with agonistic and even convulsive properties in these encephalopathic syndromes. Further investigations are needed concerning the relation of drug-induced or metabolic encephalopathies and central benzodiazepine receptor activity. We recommend a therapeutic trial with flumazenil, if stupor or decreased seizure control develop in patients treated with valproate.
26 citations
TL;DR: The antiepileptic barbexaclone is the salt of the base propylhexedrine (indirect sympathomimetic) and phenylethylbarbituric acid and its kinetics were studied after treatment with an equimolar dose of phenobarbital-Na (40 mg/kg).
Abstract: The antiepileptic barbexaclone is the salt of the base propylhexedrine (indirect sympathomimetic) and phenylethylbarbituric acid. After i.v. and oral administration of 66 mg/kg barbexaclone to mice the time course of propylhexedrine and phenobarbital concentrations was studied in plasma, brain, lung, liver, kidney, spleen, heart, and skeletal muscle. Furthermore, the kinetics of phenobarbital were studied after treatment with an equimolar dose of phenobarbital-Na (40 mg/kg).
15 citations
TL;DR: It was concluded that propylhexedrine did not affect the serum kinetics of PB given as barbexaclone, and the absorption and elimination parameters were very similar.
Abstract: The kinetics of phenobarbital (PB) was compared after oral administration of equivalent doses of the drug as the acid or the propylhexedrine salt (barbexaclone) to 7 normal volunteers. The absorption and elimination parameters were very similar. It was concluded that propylhexedrine did not affect the serum kinetics of PB given as barbexaclone.
5 citations
TL;DR: A open clinic assay with barbexaclone which is an association of phenobar-vital with light stimulant of the central nervour system (i-l-ciclohexil-2-methilaminopropane) for the treatment of epileptic disorders is reported.
Abstract: A open clinic assay with barbexaclone which is an association of phenobar-vital with light stimulant of the central nervour system (i-l-ciclohexil-2-methilaminopropane) for the treatment of epileptic disorders is reported. The authors have studied 40 patients aged between 0-12 years of age, of both sexes, all of them having convulsive seizures of the Grand Mal type associated or not to other epileptic manifestations. After analysing the different aspects of the group they consider satisfactory the results obtained: very good or good in 82,5% of the cases.
5 citations
Journal Article•
TL;DR: The therapeutic and prophylactic strategies adopted are described in detail with particular emphasis on the use of diphenylhydantoin (DPH) and barbexaclone, found to be particularly useful in the treatment of patients suffering from a post-traumatic psycho-organic syndrome in addition to the PTE.
Abstract: A report is presented on 58 patients (46 males, 12 females) all suffering from post-traumatic epilepsy (PTE) and followed up for a minimum of 1 year to maximum of 23 years after the injury (mean 6.3 years). The type and site of the head injury, the nature of the brain lesions, the time elapsing before the first critical manifestation, the clinical character of the epileptic attacks, EEG, cerebral CAT and RMN data were performed are given for all patients. The therapeutic and prophylactic strategies adopted are then described in detail with particular emphasis on the use of diphenylhydantoin (DPH) and barbexaclone. The latter drug, used for the last 3 years was found to be particularly useful in the treatment of patients suffering from a post-traumatic psycho-organic syndrome in addition to the PTE.
3 citations
Related Topics (5)
Performance Metrics
| Year | Papers |
|---|---|
| 2013 | 3 |
| 2010 | 1 |
| 2004 | 1 |
| 1993 | 1 |
| 1987 | 2 |
| 1986 | 1 |